The company will have had extremely robust discussions with the FDA and received feedback on exactly the parameters that they require to make sure the study ticks all the boxes to give the best chance for a successful outcome of the study and achieve the approval. Doing it quickly would not be part of the strategy.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-17
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.80 |
Change
-0.005(0.28%) |
Mkt cap ! $153.5M | |||
| Open | High | Low | Value | Volume |
| $1.80 | $1.81 | $1.75 | $60.57K | 33.66K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1114 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.80 | 4958 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| EMV (ASX) Chart |